News J&J's psoriasis drug faces crowded market after US approval J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
News Novartis' psoriasis drug gets label boost New label shows Cosentyx is superior to J&J's rival in long-term.
News Valeant's Siliq price undercuts rivals to offset black box w... Siliq will be cheaper than rivals from Novartis and Eli Lilly.
News Novartis cues up Cosentyx as disease-modifying treatment for... Pharma begins early intervention trial after Cosentyx shows "disease modifying" properties
News UK court overturns AbbVie Humira patents Decision paves way for cheaper competitor in autumn 2018.
News Next gen psoriasis drugs show superiority to Stelara Guselkumab can also be used if older drug Stellara fails.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
